NASA’s Breakthrough Superalloy Wins Commercial Invention of the Year NASA Glenn Research Center’s new material, GRX-810, has been recognized as the Commercial Invention of the Year by NASA’s Inventions and Contributions...more
A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11 plan to settle thousands of opioid-related lawsuits. The plan requires (1) a $6.5 billion contribution from the Sackler family...more
On October 6, 2025, FCC Chairman Brendan Carr declared October 2025 “Space Month” in an effort “to boost our country’s space economy.” The FCC’s stated goal for Space Month “is to make sure that the U.S. is the friendliest...more
No Tariffs on Aerospace Products Traded Between U.S. and European Union - On July 27, 2025, the U.S. and EU reached a trade agreement. As part of the agreement, the U.S. will impose a 15 percent tariff “on the vast majority...more
9/4/2025
/ Aerospace ,
Aviation Industry ,
Drones ,
EU ,
Exports ,
Federal Aviation Administration (FAA) ,
Imports ,
Initial Public Offering (IPO) ,
International Trade ,
NPRM ,
Proposed Rules ,
SCOTUS ,
Startups ,
Tariffs ,
US Trade Policies
On July 27, 2025, the US and EU reached a trade agreement. As part of the agreement, the US will impose a 15 percent tariff “on the vast majority of EU exports. ” President Trump signed an Executive Order on July 31...more
8/6/2025
/ Aerospace ,
Aircraft ,
Aircraft Equipment ,
Airlines ,
EU ,
Exports ,
Imports ,
International Trade ,
Tariffs ,
Trade Agreements ,
Trade Policy ,
Trump Administration ,
US Trade Policies
Congress authorized the FDA to determine whether a drug is “in shortage in the United States.” The FDA’s determination of a drug shortage triggers mechanisms designed to alleviate the shortage. For example, a determination of...more
Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals. Novartis Pharm. Corp. v. MSN Pharm. Inc., Civil Action No. 20-md-2930-RGA, Dkt. No. 1456...more
JANSSEN PHARMACEUTICALS, INC. v. TEVA PHARMACEUTICALS USA, INC.
Before Prost, Dyk, and Hughes. Appeal from the United States District Court for the District of New Jersey. Summary: District court erred by adding...more
On January 9, 2024, the USPTO published guidelines for its patent examiners when evaluating compliance with the enablement requirement in light of the U.S. Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et...more
Elekta Limited v. Zap Surgical Systems, Inc.
Before: Reyna, Stoll, and Stark. Appeal from the Patent Trial and Appeal Board.
Summary: Patentee’s failure during prosecution to distinguish relevant art provided support...more
In Sanofi-Aventis Deutschland GmbH v. Mylan Pharm. Inc., Case No. 2021-1981, the Federal Circuit reversed an obviousness determination by the PTAB. At issue was Sanofi’s reissued U.S. Patent No. RE47,614 (the ’614 patent),...more
6/13/2023
/ Analogous Art ,
Inter Partes Review (IPR) Proceeding ,
Medical Devices ,
Mylan Pharmaceuticals ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Ownership ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Prior Art ,
Sanofi-Aventis
In Re Google LLC -
Before: Moore, Lourie, and Prost. Appeal from the Patent Trial and Appeal Board.
Summary: The PTO’s arguments on appeal did not reflect the record below....more